Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epi-ON vs Epi-OFF CXL in Keratoconus
NCT03858036Phase 3Unknown
- Sponsor
- Center For Sight
- Start
- Mar 2019
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of Ricrolin in keratoconus, corneal ectasia, sponsored by Center For Sight. Status: unknown.
02
Drugs
Ricrolin
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT03858036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03858036.